Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis

Viget, N.; Vernier-Massouille, G.; Salmon-Ceron, D.; Yazdanpanah, Y.; Colombel, J.-F.
April 2008
Gut;Apr2008, Vol. 57 Issue 4, p549
Academic Journal
Because of the increasing use of immunosuppressive and biological drugs, the occurrence of opportunistic infections has become a key safety issue for patients with inflammatory bowel disease (IBD). Consequently, improvement of healthcare workers' knowledge of this domain is urgent. In this review, the preventive measures that would help to reduce the rate of opportunistic infections in patients with IBD are listed, and the management of situations frequently confronting doctors is considered. In the absence of national and international recommendations, the information given here should help doctors to optimise patient outcomes.


Related Articles

  • Opportunistic Infections With Anti-Tumor Necrosis Factor-α Therapy in Inflammatory Bowel Disease: Meta-Analysis of Randomized Controlled Trials. Ford, Alexander C; Peyrin-Biroulet, Laurent // American Journal of Gastroenterology;Aug2013, Vol. 108 Issue 8, p1268 

    OBJECTIVES:Several anti-tumor necrosis factor-α (TNFα) antibodies have demonstrated efficacy in Crohn's disease (CD) and ulcerative colitis (UC). These drugs carry the theoretical risk of opportunistic infection, but no systematic review and meta-analysis has examined this issue...

  • Cost-effectiveness of Prophylaxis Against Pneumocystis jiroveci Pneumonia in Patients with Crohn's Disease. Okafor, Philip; Farraye, Francis; Okafor, Adetoro; Erim, Daniel; Okafor, Philip N; Farraye, Francis A; Okafor, Adetoro T; Erim, Daniel O // Digestive Diseases & Sciences;Dec2015, Vol. 60 Issue 12, p3743 

    Background: Emerging evidence suggests that Pneumocystis jiroveci pneumonia is occurring more frequently in Crohn's disease patients on immunosuppressive medications, especially corticosteroids. Considering its excess mortality and the efficacy of chemoprophylaxis in reducing P....

  • Editorial: Bugs and Drugs: Insights into the Pathogenesis of Inflammatory Bowel Disease. Nguyen, Geoffrey C // American Journal of Gastroenterology;Dec2011, Vol. 106 Issue 12, p2143 

    The dysbiosis hypothesis posits that perturbations in the gut microbiome may contribute to the development of inflammatory bowel disease (IBD). A recent Canadian population-based study has shown an association between new-onset IBD and antibiotic use in the 2-5 years preceding diagnosis. Though...

  • Increased short- and long-term risk of inflammatory bowel disease after Salmonella or Campylobacter gastroenteritis.  // Inflammatory Bowel Disease Monitor;Apr2009, Vol. 10 Issue 2, p70 

    The article discusses a study concerning the increased short and long term risk of inflammatory bowel disease (IBD) after an initial diagnosis of Salmonella or Campylobacter gastroenteritis in the U.S. It mentions that the study was generated from population and case-controlled trial with...

  • Reduced mucosal antimicrobial activity in Crohn's disease of the colon. Nuding, Sabine; Fellermann, Klaus; Wehkamp, Jan; Stange, Eduard F. // Gut;Sep2007, Vol. 56 Issue 9, p1240 

    Objectives: In order to maintain the mucosal barrier against luminal microorganisms the intestinal epithelial cells synthesise various broad-spectrum antimicrobial peptides including defensins and cathelicidins. Recent studies indicate that both may be deficient in Crohn's disease. To elucidate...

  • Inflammatory Bowel Disorders.  // Current Medical Literature: Gastroenterology;2011, Vol. 30 Issue 1, p21 

    The article discusses various research that explored the different aspects of inflammatory bowel disorders. One of the studies dealt with the changes in surgical resection rates and medical treatments for Crohn's disease. Another research focused on the association of pre-operative management...

  • Targeting leukocyte migration and adhesion in Crohn's disease and ulcerative colitis. Thomas, Saskia; Baumgart, Daniel // Inflammopharmacology;Feb2012, Vol. 20 Issue 1, p1 

    Crohn's disease and ulcerative colitis are two chronic inflammatory bowel diseases. Current biologic therapies are limited to blocking tumor necrosis factor alpha. However, some patients are primary non-responders, experience a loss of response, intolerance or side effects defining the urgent...

  • New therapeutic approach in inflammatory bowel disease. PAPA, A.; MOCCI, G.; SCALDAFERRI, F.; BONIZZI, M.; FELICE, C.; ANDRISANI, G.; GASBARRINI, A. // European Review for Medical & Pharmacological Sciences;Jan2009 Supplement, Vol. 13 Issue S-1, p33 

    In the last decade, biologic agents, in particular infliximab and adalimumab, have deeply changed the therapeutic armamentarium of inflammatory bowel disease (IBD). However, these drugs have a number of contraindications and side-effects that physicians should know so to avoid and eventually...

  • Utilization of Health Care Resources by Individuals with Inflammatory Bowel Disease in the United States: A Profile of Time Since Diagnosis. Longobardi, Teresa; Jacobs, Phillip; Bernstein, Charles N. // American Journal of Gastroenterology;Apr2004, Vol. 99 Issue 4, p650 

    BACKGROUND: There are no cost studies of inflammatory bowel disease (IBD) that describe its impact on resource utilization or treatment costs over long periods of time. Our aim was to determine if there are observable trends in health-care resource utilization by adults with IBD depending on...


Read the Article


Sign out of this library

Other Topics